CAAP Company: MEDELLA HEALTH Raises $1.4 MILLION
June 2, 2016 Harry Gandhi is the co-founder of Medella Health, a Waterloo-based company developing a smart contact lens that continuously monitors glucose levels (with the information transmitted to a mobile device), is hoping that its contact lens will change the way we approach the disease. The company has raised $1.4 million in funding from 1517 Fund, Fifty Years Fund, Garage Capital, and BDC Capital.
For the full story, click here
OBIO CAAP Company: Perimeter Medical Imaging Receives FDA Clearance for OTIS Optical Tissue Imaging System
May 24, 2016 TORONTO Perimeter Medical Imaging, Inc., an innovative medical imaging company whose mission is to revolutionize tissue removal surgery for surgeons and patients, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its OTISTM 1.0 Optical Coherence Tomography System.
For the full press release, click here
Johnson & Johnson Innovation Opens JLABS @ Toronto
TORONTO, May 11, 2016 Johnson & Johnson Innovation announced the opening of JLABS @ Toronto, a new 40,000-square-foot life sciences incubator, providing entrepreneurs shared lab space and offices, modular lab suites and access to scientific, industry and capital funding experts as they work to build important and successful early-stage companies.
OBIO Hosts Annual Celebration of the Health Sciences Industry in Canada
Toronto, Ontario – May 5, 2016: Ontario Bioscience Innovation Organization (OBIO®) welcomed a prestigious group of investors, companies, MPPs and industry supporters to an intimate dinner on May 3 2016 in celebration of Canada’s health science industry. The event was supported by Torys LLP and by Bloom Burton & Co.
OBIO Launches Report on Building Canada’s Health Science Industry of the Future
Toronto, Ontario – April 29, 2016: Ontario Bioscience Innovation Organization (OBIO®) today released its report “How Canada Should be Engaging in a $9 Trillion Dollar Health Economy”. The report is the output of interviews and surveys of 125 CEOs of Canada’s health science companies looking at the future of the global industry and opportunities for Ontario and Canada.
OBIO brings Innovation in Action to Queen’s Park
Toronto, Ontario – April 11, 2016: Ontario Bioscience Innovation Organization (OBIO®) hosted its annual Queen’s Park Advocacy Day on April 5, attracting an impressive 150 attendees including 50 elected officials.
OBIO CAAP Company: ChipCare on the Business News Network's "The Disruptors"
ChipCare was featured on BNN's The Disruptors this week. The focus of the interview was ChipCare's differentiation to Theranos, our Series B raise and product pipeline, and our initial focus on low and middle income countries as a smart market entry approach.
Federal Budget Misses Opportunity to Scale and Grow Health Science Companies
The 2016 Federal Liberal budget contains funding to support a much needed Innovation Agenda and promises to build globally competitive companies. At the same time the majority of this funding is directed to incubators and accelerators, granting councils and public institutions to support basic research. In order to compete in the $9 trillion global health science economy, Canada needs to devote financial resources to health science companies at the next stage of development by investing in scale up, job creation and revenue generation.
CAAP Company: Komodo Openlab's Tecla Launches With Bell To Provide Customers Hands-Free Access To Mobile Technology
TORONTO, Monday, February 29, 2016 — Tecla, the assistive device that provides hands-free access to technology for those with limited upper-body mobility, is about to get a whole lot more accessible for Bell customers.
OBIO Announces CONAVI Medical WINNER of OBIO First Annual Pitches and Pitchers Competition
Last night, OBIO held its first annual PITCHES AND PITCHERS COMPETITION for OBIO Pre-CAAP and CAAP companies. We are pleased to announce that Stefano Picone, Director of Finance, CONAVI Medical, received the most votes from his peers and won the competition!!
Click here for a picture of the winner!
CAAP Company: ScarX Therapeutics closes $2 million Series A financing
Feb. 16, 2016 Toronto - ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis), has closed a $2 million Series A financing. The company will complete a Phase I clinical trial of its lead candidate, SCX-001, in human volunteers, with the eventual goal of creating better functional and cosmetic patient outcomes.
OBIO applauds federal funding for Natural Products Canada
February 12, 2016 – Toronto Ontario. Today, the Ontario Bioscience Innovation Organization welcomes the creation of Natural Products Canada Inc. (NPC), the nation’s newest Centre of Excellence for Commercialization and Research. Press Release. Click here for the press release.
CAAP Company: Conavi Medical (formerly Colibri Technologies) announces FDA 510k clearance for its first product, the Foresight ICE System for Intracardiac Echocardiography
TORONTO, Jan. 14, 2016 /PRNewswire/ - Conavi Medical Inc. (formerly Colibri Technologies Inc.) has received United States (US) Food and Drug Administration (FDA) 510(k) clearance for the Foresight ICE System for intracardiac and intraluminal ultrasound visualization of cardiac and great vessel anatomy as well as visualization of other devices in the heart and great vessels of patients
CAAP Company: Induce Biologics Signs Exclusive License & Distribution Agreement with Antibe Therapeutics
January 12, 2016, Toronto — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF), a commercial-stage healthcare company focused on pain, inflammation and regenerative medicine, is pleased to announce the signing of an exclusive Licensing and Distribution Agreement with Induce Biologics Inc. (“Induce”) for the Canadian rights for Induce’s URIST(TM) biological product for dental and craniofacial applications.
For the full press release click here
Gail Garland, OBIO CEO talks with BNN about Canada's health science industry
Gail Garland, OBIO CEO talks with BNN about the economic and health benefits that accrue to Canada by building a globally competitive Canadian health science industry. Click here for the full interview.
Canada needs a strategy to reach its biotech potential
Canada has a well-known research sector and relatively strong infrastructure to nurture startups, but once biotech companies start to grow, they often stall and struggle for resources.
Ontario Bioscience Innovation Organization Announces Election of Shelley Boyd, Jeremy Bridge-Cook, Michael Cloutier and Cathy Szabo to its Board of Directors
Toronto, Ontario, November 4, 2015 – Ontario Bioscience Innovation Organization (“OBIO®”), a non-profit organization that is Ontario’s leading advocate for the life science sector, announces the election of four new members to its Board of Directors: Shelley Boyd, Jeremy Bridge-Cook, Michael Cloutier and Cathy Szabo.
Ontario Bioscience Innovation Organization Announces a Call for Applications for the 2016 Capital Access Advisory Program
Toronto, Ontario, November 3, 2015 – Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit organization that is Ontario’s leading advocate for the life sciences sector, is pleased to announce a call for applications for the 2016 OBIO Capital Access Advisory Program (CAAP®).
Ontario Bioscience Innovation Organization Congratulates Ontario on the Appointment of Chief Health Innovation Strategist
Today, Ontario Bioscience Innovation Organization (OBIO®) released a statement congratulating the Government of Ontario on the appointment of William Charnetski as Ontario’s first Chief Health Innovation Strategist.
“OBIO congratulates Mr. Charnetski on his appointment to this pivotal role,” said Gail Garland, Chief Executive Officer of OBIO. “We look forward to supporting his efforts to catalyze adoption of innovative health technologies which strengthen the province’s capacity to deliver cost-effective, outcome-focused care for patients.”
OBIO Congratulates and Welcomes Johnson & Johnson Innovation, JLABS to the Ontario Bioscience Ecosystem
Toronto, Ontario, September 21, 2015 – The Ontario Bioscience Innovation Organization (OBIO®) is pleased to recognise Johnson & Johnson Innovation’s major contribution to Ontario’s human health bioscience ecosystem through the choice of Toronto as the first ex-US Johnson & Johnson Innovation, JLABS site. The JLABS incubator model is the highly successful creation of Johnson & Johnson Innovation and has been brought to Canada with the help of Janssen Inc. Known as JLABS @ Toronto, the site will join its fellow JLABS sites in San Diego, San Francisco, Boston and Houston.